the significance of biomarkers in abdominal drain fluid for anastomotic leakage.

Not Applicable

• Conditions: Health Condition 1: K639- Disease of intestine, unspecified

• Registration Number: CTRI/2024/06/069141
• Lead Sponsor: AIIMS NEW DELHI

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 24 June 2024

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. 18 – 70 Years

2. Both gender

3. Post-operative abdominal surgery undergone intestinal anastomosis

4. Patients can follow instructions and are ready for regular follow up

5. Able to provide informed and written consent

6. Non-trauma elective and emergency cases with small intestine perforation or obstruction.

7. Mesenteric ischemia or strangulation: Small Intestinal obstruction with segmental ischemia or gangrene

8. Tumour: small bowel mass , Small bowel malignancy with adequate negative margin

9. Entero-cutaneous fistula

10. Symptomatic benign disease such as Meckles diverticulum or perforated diverticulitis or intussusception of bowel needing resection and anastomosis

11. Incarcerated hernia

12. Patients with ileostomy for closure

Exclusion Criteria

1. Age less than 18 years and more than 70 years

2. Patients taking immunosuppressive therapy and chemotherapy.

3. Patients with known hematological disorders or malignancy.

4. Patients with known chronic liver or kidney disease

5. Auto-immune disease or immunodeficiency syndrome

6. Pregnant or lactating mother

7. Refusal to consent or participate in the study

8. Proximal diverting ostomy creation at the time of intestinal anastomosis

9. Patients receiving Albumin Supplementation during the period of the study.

10. Abdominal trauma with small intestine perforation or obstruction.

11. Active inflammatory bowel disease (Crohn’s enteritis with complications)

12. Anastomosis involving oesophagus, stomach, duodenum, colon and rectum

13. Patients on immunosuppressive drugs, post-chemotherapy or post-radiotherapy

Study & Design

• Study Type: Observational
• Study Design: Not specified